More and more, it seems like long-term success in chemicals and specialty materials is all about keeping an open mind toward reinvention. DuPont (NYSE:DD), for instance, is far removed from its legacy in products like gunpowder and nylon, and currently looks to advanced seed traits and nutrition as important growth markets. Likewise, DSM has moved on from coal, fertilizer and petrochemicals into areas like nutrition and biofuels.

DuPont's German cousin BASF (OTC:BASFY) is following in this path, announcing on Wednesday that it had reached an agreement to acquire Norwegian fish oil specialist Pronova for 12.50 Norwegian kroner per share, or about $845 million in enterprise value.

Credit Card Comparison: Find the credit card that is just right for you

A Cheap Deal for a High-Quality Supplement
At $845 million, BASF would be paying less than six times EV/EBITDA and only about a 4% premium to Pronova's close a day before the deal. With quite a bit of interest of late in the fish oil space, not to mention the low bid valuation, Pronova's shares are trading slightly above the bid value. Keep in mind, however, that shareholders holding more than half of Pronova's shares have agreed to the deal, though European laws give objecting minority investors more rights and leverage than in the United States.

Pronova is a leading supplier of pharmaceutical-grade fish oils - supplying the active ingredients for heart/cholesterol drug Lovaza (aka Omacor) to GlaxoSmithKline (NYSE:GSK) and Abbott Labs (NYSE:ABT). Pronova has also been actively looking to build outside of the pharmaceutical space, looking to position its fish oils into markets like clinical nutrition (parental nutrition), supplements, infant formulas and food additives - particularly those markets where especially high-grade concentrates can attract appealing pricing, and to do that they needed to turn to mergers and acquisitions.

This is not BASF's first foray into fish oil. BASF bought Equatec earlier this year, and Pronova should vault it into a leading market position in Europe and the U.S. alongside companies like Croda and DSM (which has spent about $1.6 billion over the past 18 months on Martek and Ocean Nutrition, and holds a leading share in concentrates for infant formulas).

A Deal That Says Little-to-Nothing for Amarin
One of the most controversial stocks of late in biotech has been Amarin (Nasdaq:AMRN) - an Irish biotech that has developed a highly purified omega-3 product (Vascepa) for heart disease. There has been ample debate about the sales prospects for Vascepa, including suggestions that doctors are turning away from omega-3 fatty acids/fish oil as a treatment for cholesterol and heart disease. Even more controversial is the question as to whether Amarin can secure New Chemical Entity (NCE) status from the FDA and with it, enhanced protection from potential generic competition.

Amarin has also been pegged as a company in play, with investors openly speculating on which Big Pharma may offer shareholders a lucrative buyout.

This BASF-Pronova deal, however, would seem to have little to do directly with Amarin. While it's true that Pronova supplies the key ingredient(s) for Lovaza, the drug has gone generic in Europe and will go off-patent in the U.S. in 2017. While the bulk of Pronova's revenue and profits today come from Lovaza, BASF management was quite clear that they saw the real value in the deal coming from the ongoing growth of fish oil/omega-3 fatty acids as supplements and food additives. For instance, BASF estimated that the current omega-3 concentrate market is worth about $1.1 billion today and likely to grow to over $2 billion by the end of this decade.

What's more, and I believe this is a key detail, Amarin does not produce the the ethyl-EPA that serves as the active ingredient to Vascepa. In Pronova, BASF is buying one of the largest independent producers of highly purified/concentrated omega-3 fatty acids, whereas a buyer of Amarin would primarily be acquiring the rights to market that particular formulation as a prescription treatment for heart diseases and/or high cholesterol. Consequently, I don't think Amarin investors can use the BASF-Pronova as any sort of real benchmark or comparable for a possible deal for their company.

The Bottom Line
As recent deals like Nestle's (OTC:NSRGY) bid for Pfizer's (NYSE:PFE) infant nutrition business and Reckitt Benckiser's (OTC:RBGPY) deal for Schiff Nutrition (NYSE:SHF) suggest, there is considerable interest these days in nutrition as a growth market. What's more, the M&A activity of DSM and BASF makes it sound like there's going to be considerable ongoing interest in exploiting fish oils and omega-3 fatty acids to improve the nutritional content of a wide range of food products, including infant formula.

Even with the support of major shareholders, BASF may not have Pronova wrapped up just yet. I would not be surprised to see a rival bidder step up, particularly since the valuation is not all that demanding yet. Whether a company like Bayer (OTC:BAYRY), frustrated in its attempt to buy Schiff, steps up, odds are that fish oils and omega-3 fatty acids are going to find their way into more and more clinical and consumer products in the years to come.

At the time of writing, Stephen D. Simpson did not own any shares in any company mentioned in this article.

Related Articles
  1. Investing

    How to Ballast a Portfolio with Bonds

    If January and early February performance is any guide, there’s a new normal in financial markets today: Heightened volatility.
  2. Stock Analysis

    Performance Review: Emerging Markets Equities in 2015

    Find out why emerging markets struggled in 2015 and why a half-decade long trend of poor returns is proving optimistic growth investors wrong.
  3. Investing News

    The UAE: An Emerging Economy for Investors

    The learning from UAE on how it succeeded with timely diversification when the BRICS nations and the neighboring oil-rich economies faced challenges.
  4. Investing News

    Today's Sell-off: Are We in a Margin Liquidation?

    If we're in market liquidation, is it good news or bad news? That party depends on your timeframe.
  5. Investing News

    Bank Stocks: Time to Buy or Avoid? (WFC, JPM, C)

    Bank stocks have been pounded. Is this the right time to buy or should they be avoided?
  6. Stock Analysis

    Why the Bullish Are Turning Bearish

    Banks are reducing their targets for the S&P 500 for 2016. Here's why.
  7. Stock Analysis

    How to Find Quality Stocks Amid the Wreckage

    Finding companies with good earnings and hitting on all cylinders in this environment, although possible, is not easy.
  8. Investing News

    What You Can Learn from Carl Icahn's Mistakes

    Carl Icahn has been a stellar performer in the investment world for decades, but following his lead these days could be dangerous.
  9. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
  10. Investing News

    Icahn's Bet on Cheniere Energy: Should You Follow?

    Investing legend Carl Icahn continues to lose money on Cheniere Energy, but he's increasing his stake. Should you follow his lead?
RELATED FAQS
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
COMPANIES IN THIS ARTICLE
Trading Center